What is VolitionRx?
VolitionRx is a life sciences company dedicated to the development of innovative diagnostic tests for cancer and other conditions. Leveraging the science of Nucleosomics, the company aims to identify and measure nucleosomes in bodily fluids as indicators of disease. Their objective is to create diagnostic tests that are as accessible and straightforward to use as current diabetic and cholesterol blood tests for both patients and healthcare providers. VolitionRx's research and development efforts are primarily based in Belgium, with a strategic focus on launching its diagnostic products initially in Europe, followed by the U.S. market, and eventually, a global rollout.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $5.7M across 3 funding rounds:
Debt
$1.2M
Debt
$500K
Other Financing Round
$4M
Debt (2017): $1.2M with participation from SOFINEX
Debt (2019): $500K led by Texas A&M SOFINEX
Other Financing Round (2021): $4M supported by Namur Invest
Key Investors in VolitionRx
Namur Invest
Namur Invest is a financial partner focused on businesses within the Namur province, providing diverse financing solutions to enhance financial structures for medium and long-term growth. They invest in projects with development potential and value creation, supporting company creation, innovation, and expansion.
SOFINEX
SOFINEX is a financial entity that has provided debt financing to VolitionRx, indicating a role in supporting the company's operational and growth initiatives through credit facilities.
Texas A&M SOFINEX
Texas A&M SOFINEX has participated in debt financing rounds for VolitionRx, suggesting a supportive role in the company's capital structure and expansion plans.
What's next for VolitionRx?
The recent major strategic investment signals a pivotal phase for VolitionRx, likely enabling the company to accelerate its product development pipeline and expand its market reach. With a clear focus on bringing its Nucleosomics-based diagnostics to market, this capital infusion is expected to support regulatory approvals, manufacturing scale-up, and commercialization efforts in key regions. The company's trajectory suggests a move towards scaling operations and solidifying its position in the competitive diagnostic testing landscape.
See full VolitionRx company page
